|
 |
|
|||||||
|
|||||||||
Diabetes 51:3283-3289, 2002
© 2002 by the American Diabetes Association, Inc.
ALT-946 and Aminoguanidine, Inhibitors of Advanced Glycation, Improve Severe Nephropathy in the Diabetic Transgenic (mREN-2)27 Rat
1 Department of Physiology, University of Melbourne, Parkville, Victoria, Australia
2 Department of Medicine, St. Vincent’s Hospital, Fitzroy, Victoria, Australia
3 Department of Medicine, the Austin Repatriation Hospital Medical Centre, West Heidelberg, Victoria, Australia
The severe diabetic nephropathy that develops in the hypertensive transgenic (mRen-2)27 rat with streptozotocin (STZ) diabetes has previously been considered angiotensin II-dependent. Because metabolic pathways are also activated in the diabetic kidney, the present study aimed to determine whether renoprotection could be afforded with inhibitors of advanced glycation end products (AGEs), ALT-946, and aminoguanidine (AG). At 6 weeks of age, nondiabetic control and STZ diabetic Ren-2 rats were randomized to receive vehicle, ALT-946 (1 g/l), or AG (1 g/l) and were studied for 12 weeks. Systolic blood pressure was unchanged with diabetes, ALT-946, or AG. Both kidney weight and glomerular filtration rate were increased with diabetes and unchanged with ALT-946 or AG. ALT-946 and AG equally ameliorated glomerulosclerosis and medullary pathology; however, ALT-946 did reduce cortical tubular degeneration to a greater extent than AG. Albumin excretion rate, which was elevated with diabetes, was reduced with ALT-946 but not AG. AGE immunolabeling was increased in glomeruli and reduced with ALT-946 and AG. These findings indicate that even in the context of renal injury presumed to be primarily blood pressure- and/or angiotensin II-dependent, approaches that interfere with metabolic pathways such as inhibitors of AGE formation can confer renal protection in experimental diabetes.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Hartner, N. Cordasic, B. Klanke, M. Wittmann, R. Veelken, and K. F. Hilgers Renal injury in streptozotocin-diabetic Ren2-transgenic rats is mainly dependent on hypertension, not on diabetes Am J Physiol Renal Physiol, February 1, 2007; 292(2): F820 - F827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury Circulation, August 8, 2006; 114(6): 597 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Huebschmann, J. G. Regensteiner, H. Vlassara, and J. E.B. Reusch Diabetes and Advanced Glycoxidation End Products. Diabetes Care, June 1, 2006; 29(6): 1420 - 1432. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Genuth, W. Sun, P. Cleary, D. R. Sell, W. Dahms, J. Malone, W. Sivitz, V. M. Monnier, and for the DCCT Skin Collagen Ancillary Study Group Glycation and Carboxymethyllysine Levels in Skin Collagen Predict the Risk of Future 10-Year Progression of Diabetic Retinopathy and Nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications Participants With Type 1 Diabetes Diabetes, November 1, 2005; 54(11): 3103 - 3111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Thomas, C. Tikellis, W. M. Burns, K. Bialkowski, Z. Cao, M. T. Coughlan, K. Jandeleit-Dahm, M. E. Cooper, and J. M. Forbes Interactions between Renin Angiotensin System and Advanced Glycation in the Kidney J. Am. Soc. Nephrol., October 1, 2005; 16(10): 2976 - 2984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I.-H. Pang, E. C. Johnson, L. Jia, W. O. Cepurna, A. R. Shepard, M. R. Hellberg, A. F. Clark, and J. C. Morrison Evaluation of Inducible Nitric Oxide Synthase in Glaucomatous Optic Neuropathy and Pressure-Induced Optic Nerve Damage Invest. Ophthalmol. Vis. Sci., April 1, 2005; 46(4): 1313 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines Endocr. Rev., December 1, 2004; 25(6): 971 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Zhou, C. Li, and L. Cai Advanced Glycation End-Products Induce Connective Tissue Growth Factor-Mediated Renal Fibrosis Predominantly through Transforming Growth Factor {beta}-Independent Pathway Am. J. Pathol., December 1, 2004; 165(6): 2033 - 2043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nangaku, T. Miyata, T. Sada, M. Mizuno, R. Inagi, Y. Ueda, N. Ishikawa, H. Yuzawa, H. Koike, C. van Ypersele de Strihou, et al. Anti-Hypertensive Agents Inhibit In Vivo the Formation of Advanced Glycation End Products and Improve Renal Damage in a Type 2 Diabetic Nephropathy Rat Model J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1212 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wendt, N. Tanji, J. Guo, B. I. Hudson, A. Bierhaus, R. Ramasamy, B. Arnold, P. P. Nawroth, S. F. Yan, V. D'Agati, et al. Glucose, Glycation, and RAGE: Implications for Amplification of Cellular Dysfunction in Diabetic Nephropathy J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1383 - 1395. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |